Tau kinetics in Alzheimer's disease

被引:13
作者
Hier, Daniel B. [1 ,2 ]
Azizi, Sima [1 ]
Thimgan, Matthew S. [3 ]
Wunsch II, Donald C. C. [1 ,4 ]
机构
[1] Missouri Univ Sci & Technol, Dept Elect & Comp Engn, Appl Computat Intelligence Lab, Rolla, MO 65409 USA
[2] Univ Illinois, Dept Neurol & Rehabil, Chicago, IL 60607 USA
[3] Missouri Univ Sci & Technol, Dept Biol Sci, Rolla, MO USA
[4] Natl Sci Fdn, ECCS Div, Alexandria, VA USA
基金
美国国家科学基金会;
关键词
tau; Alzheimer's disease; CSF levels; plasma levels; steady state kinetics; halflife; turnover; clearance; FIBRILLARY ACIDIC PROTEIN; BRAIN INTERSTITIAL FLUID; NORMAL ORGAN WEIGHTS; II-THE-BRAIN; LONGITUDINAL STABILITY; MOUSE MODEL; PLASMA TAU; SECRETION; TURNOVER; SERUM;
D O I
10.3389/fnagi.2022.1055170
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
The cytoskeletal protein tau is implicated in the pathogenesis of Alzheimer's disease which is characterized by intra-neuronal neurofibrillary tangles containing abnormally phosphorylated insoluble tau. Levels of soluble tau are elevated in the brain, the CSF, and the plasma of patients with Alzheimer's disease. To better understand the causes of these elevated levels of tau, we propose a three-compartment kinetic model (brain, CSF, and plasma). The model assumes that the synthesis of tau follows zero-order kinetics (uncorrelated with compartmental tau levels) and that the release, absorption, and clearance of tau is governed by first-order kinetics (linearly related to compartmental tau levels). Tau that is synthesized in the brain compartment can be released into the interstitial fluid, catabolized, or retained in neurofibrillary tangles. Tau released into the interstitial fluid can mix with the CSF and eventually drain to the plasma compartment. However, losses of tau in the drainage pathways may be significant. The kinetic model estimates half-life of tau in each compartment (552 h in the brain, 9.9 h in the CSF, and 10 h in the plasma). The kinetic model predicts that an increase in the neuronal tau synthesis rate or a decrease in tau catabolism rate best accounts for observed increases in tau levels in the brain, CSF, and plasma found in Alzheimer's disease. Furthermore, the model predicts that increases in brain half-life of tau in Alzheimer's disease should be attributed to decreased tau catabolism and not to increased tau synthesis. Most clearance of tau in the neuron occurs through catabolism rather than release to the CSF compartment. Additional experimental data would make ascertainment of the model parameters more precise.
引用
收藏
页数:13
相关论文
共 93 条
[11]   Constitutive secretion of tau protein by an unconventional mechanism [J].
Chai, Xiyun ;
Dage, Jeffrey L. ;
Citron, Martin .
NEUROBIOLOGY OF DISEASE, 2012, 48 (03) :356-366
[12]   The influence of cerebrospinal fluid turnover on age-related changes in cerebrospinal fluid protein concentrations [J].
Chen, Carl P. C. ;
Chen, Ruo Li ;
Preston, Jane E. .
NEUROSCIENCE LETTERS, 2010, 476 (03) :138-141
[13]   Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease [J].
Chesser, Adrianne S. ;
Pritchard, Susanne M. ;
Johnson, Gail V. W. .
FRONTIERS IN NEUROLOGY, 2013, 4
[14]   Plasma Tau Levels in Cognitively Normal Middle-Aged and Older Adults [J].
Chiu, Ming-Jang ;
Fan, Ling-Yun ;
Chen, Ta-Fu ;
Chen, Ya-Fang ;
Chieh, Jen-Jei ;
Horng, Herng-Er .
FRONTIERS IN AGING NEUROSCIENCE, 2017, 9
[15]   No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF [J].
Cicognola, Claudia ;
Chiasserini, Davide ;
Eusebi, Paolo ;
Andreasson, Ulf ;
Vanderstichele, Hugo ;
Zetterberg, Henrik ;
Parnetti, Lucilla ;
Blennow, Kaj .
MOLECULAR NEURODEGENERATION, 2016, 11
[16]   Computational modeling of tau pathology spread reveals patterns of regional vulnerability and the impact of a genetic risk factor [J].
Cornblath, Eli J. ;
Li, Howard L. ;
Changolkar, Lakshmi ;
Zhang, Bin ;
Brown, Hannah J. ;
Gathagan, Ronald J. ;
Olufemi, Modupe F. ;
Trojanowski, John Q. ;
Bassett, Danielle S. ;
Lee, Virginia M. Y. ;
Henderson, Michael X. .
SCIENCE ADVANCES, 2021, 7 (24)
[17]  
Dadas Aaron, 2018, Concussion, V3, pCNC53, DOI 10.2217/cnc-2017-0019
[18]   Improving the clinical management of traumatic brain injury through the pharmacokinetic modeling of peripheral blood biomarkers [J].
Dadas, Aaron ;
Washington, Jolewis ;
Marchi, Nicola ;
Janigro, Damir .
FLUIDS AND BARRIERS OF THE CNS, 2016, 13
[19]   Protein quality control in Alzheimer's disease by the ubiquitin proteasome system [J].
de Vrij, FMS ;
Fischer, DF ;
van Leeuwen, FW ;
Hol, EM .
PROGRESS IN NEUROBIOLOGY, 2004, 74 (05) :249-270
[20]   Antisense Reduction of Tau in Adult Mice Protects against Seizures [J].
DeVos, Sarah L. ;
Goncharoff, Dustin K. ;
Chen, Guo ;
Kebodeaux, Carey S. ;
Yamada, Kaoru ;
Stewart, Floy R. ;
Schuler, Dorothy R. ;
Maloney, Susan E. ;
Wozniak, David F. ;
Rigo, Frank ;
Bennett, C. Frank ;
Cirrito, John R. ;
Holtzman, David M. ;
Miller, Timothy M. .
JOURNAL OF NEUROSCIENCE, 2013, 33 (31) :12887-12897